VIDEO: PCSK9 inhibitor lerodalcibep shows LDL cholesterol reduction
ATLANTA — In this Healio video exclusive, Erica S. Spatz, MD, MHS, discusses research into lipid disorders from the American College of Cardiology Scientific Session, examining results of the LIBerate-HR trial on LDL cholesterol levels.
Spatz, an associate professor of cardiology and epidemiology at Yale University School of Medicine, discussed the study, which tested the novel PCSK9 inhibitor lerodalcibep (LIB003, LIB Therapeutics) and produced results noting a “significant” LDL reduction with a low treatment burden for patients.
“This is an exciting trial to look out for in the future. We need to see if this PCSK9 inhibitor also reduces cardiovascular events, and that trial is ongoing at present,” Spatz said.
Collapse
Read more about